Top

Current Treatment Options in Gastroenterology

Published in:

01-03-2020 | Esophagitis | Esophagus (P Iyer, Section Editor)

New Developments in the Diagnosis and Management of Gastroesophageal Reflux

Authors: Yan Jiang, MD, John O. Clarke, MD

Published in: Current Treatment Options in Gastroenterology | Issue 1/2020

Abstract

Purpose of review

To examine recent key developments in the pathophysiology, diagnosis, and treatment of gastroesophageal reflux disease (GERD).

Recent findings

Newer research has suggested cytokine-mediated inflammation may play a role in the physiology of GERD, implying that the underlying mechanism may not be entirely related to chemical damage due to acid. Aided by novel technologies, diagnostic testing is also moving toward elucidating individual mechanisms and better defining specific GERD phenotypes with the goal of providing directed therapy. This is especially important in current times given the increase in coverage of adverse events reportedly linked to long-term proton pump inhibitor use.

Summary

As patients are looking for potential alternatives, we highlight the key recent updates in pathophysiology and understanding of GERD and current medical and endoscopic/surgical options and explore the exciting treatments in the pipeline.

El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80. https://doi.org/10.1136/gutjnl-2012-304,269.CrossRefPubMed

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28; quiz 29. https://doi.org/10.1038/ajg.2012.444.CrossRefPubMed

Vela MF. Diagnostic work-up of GERD. Gastrointestinal endoscopy clinics of North America. 2014;24(4):655–66. https://doi.org/10.1016/j.giec.2014.07.002.CrossRef

Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2016. Am J Health-Syst Pharm: AJHP: official journal of the American Society of Health-System Pharmacists. 2016;73(14):1058–75. https://doi.org/10.2146/ajhp160205.CrossRef

Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. https://doi.org/10.1053/j.gastro.2017.04.047A review of studies examing PPI related adverse effects that concludes there is inadequate evidence to establish causal relationships of many reported effects. Recommends continued use in those with proven indication for PPI but discourages dose escalation and chronic therapy for those unresponsive to initial empiric trial. CrossRefPubMed

Dunbar KB, Agoston AT, Odze RD, Huo X, Pham TH, Cipher DJ, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. Jama. 2016;315(19):2104–12. https://doi.org/10.1001/jama.2016.5657A study examining esophageal biopsies of those with reflux esophagitis which showed an increase in T lymphocytes, providing evidence to suggest that cytokine mediated inflammation plays a role in mucosal injury. CrossRefPubMedPubMedCentral

Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137(5):1776–84. https://doi.org/10.1053/j.gastro.2009.07.055.CrossRefPubMed

Huo X, Agoston AT, Dunbar KB, Cipher DJ, Zhang X, Yu C, et al. Hypoxia-inducible factor-2alpha plays a role in mediating oesophagitis in GORD. Gut. 2017;66(9):1542–54. https://doi.org/10.1136/gutjnl-2016-312,595.CrossRefPubMed

Woodland P, Shen Ooi JL, Grassi F, Nikaki K, Lee C, Evans JA, et al. Superficial esophageal mucosal afferent nerves may contribute to reflux hypersensitivity in nonerosive reflux disease. Gastroenterology. 2017;153(5):1230–9. https://doi.org/10.1053/j.gastro.2017.07.017.CrossRefPubMed

10.

Corning B, Copland AP, Frye JW. The esophageal microbiome in health and disease. Curr Gastroenterol Rep. 2018;20(8):39. https://doi.org/10.1007/s11894-018-0642-9.CrossRef

11.

Okereke I, Hamilton C, Wenholz A, Jala V, Giang T, Reynolds S, et al. Associations of the microbiome and esophageal disease. J Thorac Disease. 2019;11(Suppl 12):S1588–s93. https://doi.org/10.21037/jtd.2019.05.82.CrossRef

12.

Hirano I, Pandolfino JE, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders: expert review from the clinical practice updates committee of the AGA Institute. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2017;15(3):325–34. https://doi.org/10.1016/j.cgh.2016.10.022.CrossRef

13.

Scarpulla G, Camilleri S, Galante P, Manganaro M, Fox M. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. Am J Gastroenterol. 2007;102(12):2642–7. https://doi.org/10.1111/j.1572-0241.2007.01461.x.CrossRefPubMed

14.

Barrett C, Choksi Y, Vaezi MF. Mucosal impedance: a new approach to diagnosing gastroesophageal reflux disease and eosinophilic esophagitis. Curr Gastroenterol Rep. 2018;20(7):33. https://doi.org/10.1007/s11894-018-0639-4.CrossRefPubMed

15.

Bakalar N Heartburn drugs can lead to fatal heart or kidney disease. New York Times. 2019 .

16.

Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53(7):1024–31. https://doi.org/10.1136/gut.2003.033290.CrossRefPubMedPubMedCentral

17.

Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout A, et al. Modern diagnosis of GERD: the Lyon consensus. Gut. 2018;67(7):1351–62. https://doi.org/10.1136/gutjnl-2017-314,722Consensus statement defining specific GERD populations. Highlights conclusive endoscopic criteria for GERD, pH testing indications on/off PPI, abnormal pH testing parameters and current role of high resolution manometry. CrossRefPubMedPubMedCentral

18.

Chae S, Richter JE. Wireless 24, 48, and 96 hour or impedance or oropharyngeal prolonged pH monitoring: which test, when, and why for GERD. Curr Gastroenterol Rep. 2018;20(11):52. https://doi.org/10.1007/s11894-018-0659-0.CrossRefPubMed

19.

Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2005;3(11):1083–8.CrossRef

20.

Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-h periods off and on PPI therapy. Am J Gastroenterol. 2008;103(7):1631–7. https://doi.org/10.1111/j.1572-0241.2008.01829.x.CrossRefPubMed

21.

Patel RCS, Jacobs J, Kumar A, Richter J. 96-h esophageal pH monitoring: the tiebreaker for abnormal DeMeester score and symptom index. Gastroenterology. 2018;154(6):S-487-7.

22.

Patel DA, Vaezi MF. Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease. Curr Opin Gastroenterol. 2017;33(4):277–84. https://doi.org/10.1097/mog.0000000000000367.CrossRefPubMed

23.

Frazzoni M, de Bortoli N, Frazzoni L, Tolone S, Furnari M, Martinucci I et al. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. Neurogastroenterol Motil: the official journal of the European Gastrointestinal Motility Society. 2017;29(3). doi:https://doi.org/10.1111/nmo.12947.CrossRef

24.

Patel A, Wang D, Sainani N, Sayuk GS, Gyawali CP. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2016;44(8):890–8. https://doi.org/10.1111/apt.13777.CrossRefPubMedPubMedCentral

25.

Saritas Yuksel E, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, Garrett CG, et al. Use of direct, endoscopic-guided measurements of mucosal impedance in diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2012;10(10):1110–6. https://doi.org/10.1016/j.cgh.2012.05.018.CrossRef

26.

Ates F, Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology. 2015;148(2):334–43. https://doi.org/10.1053/j.gastro.2014.10.010.CrossRefPubMed

27.

Patel DA, Higginbotham T, Slaughter JC, Aslam M, Yuksel E, Katzka D, et al. Development and validation of a mucosal impedance contour analysis system to distinguish esophageal disorders. Gastroenterology. 2019;156(6):1617–26.e1. https://doi.org/10.1053/j.gastro.2019.01.253.CrossRefPubMed

28.

Tucker E, Sweis R, Anggiansah A, Wong T, Telakis E, Knowles K, et al. Measurement of esophago-gastric junction cross-sectional area and distensibility by an endolumenal functional lumen imaging probe for the diagnosis of gastro-esophageal reflux disease. Neurogastroenterol Motil: the official journal of the European Gastrointestinal Motility Society. 2013;25(11):904–10. https://doi.org/10.1111/nmo.12218.CrossRef

29.

Rinsma NF, Smeets FG, Bruls DW, Kessing BF, Bouvy ND, Masclee AA, et al. Effect of transoral incisionless fundoplication on reflux mechanisms. Surg Endosc. 2014;28(3):941–9. https://doi.org/10.1007/s00464-013-3250-7.CrossRefPubMed

30.

Ilczyszyn A, Botha AJ. Feasibility of esophagogastric junction distensibility measurement during Nissen fundoplication. Diseases Esophagus: official journal of the International Society for Diseases of the Esophagus. 2014;27(7):637–44. https://doi.org/10.1111/dote.12130.CrossRef

31.

Oshima T, Miwa H. Potent potassium-competitive acid blockers: a neweEra for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334–44. https://doi.org/10.5056/jnm18029.CrossRefPubMedPubMedCentral

32.

Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomized clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–51. https://doi.org/10.1111/apt.13461.CrossRefPubMed

33.

Di Stefano M, Papathanasopoulos A, Blondeau K, Vos R, Boecxstaens V, Farre R, et al. Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers. Diseases Esophagus: official journal of the International Society for Diseases of the Esophagus. 2012;25(5):470–6. https://doi.org/10.1111/j.1442-2050.2011.01275.x.CrossRef

34.

Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther. 2016;18:195. https://doi.org/10.1186/s13075-016-1094-y.CrossRefPubMedPubMedCentral

35.

Aggarwal N, Thota PN, Lopez R, Gabbard S. A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. Neurogastroenterol Motil: the official journal of the European Gastrointestinal Motility Society. 2018;30(2). doi:https://doi.org/10.1111/nmo.13213.CrossRef

36.

Thomas E, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J. Randomized clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2014;39(6):595–602. https://doi.org/10.1111/apt.12640.CrossRefPubMed

37.

Wilkinson JWA, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2019;31(1):86–93.CrossRef

38.

Clarke JO, Fernandez-Becker NQ, Regalia KA, Triadafilopoulos G. Baclofen and gastroesophageal reflux disease: seeing the forest through the trees. Clin Transl Gastroenterol. 2018;9(3):137. https://doi.org/10.1038/s41424-018-0010-y.CrossRefPubMedPubMedCentral

39.

Lei WY, Hung JS, Liu TT, Yi CH, Chen CL. Influence of GABA-B agonist baclofen on capsaicin-induced excitation of secondary peristalsis in humans. Clin Transl Gastroenterol. 2017;8(10):e120. https://doi.org/10.1038/ctg.2017.46.CrossRefPubMedPubMedCentral

40.

Vaezi MF, Fass R, Vakil N, Mittleman R, Hall M, Reasner DS, et al. 875 - Iw-3718, a novel gastric-retentive bile acid sequestrant, improved heartburn and regurgitation symptoms in patients with persistent gerd despite PPI treatment: a double-blind, placebo-controlled study. Gastroenterology. 2018;154(6):S-174. https://doi.org/10.1016/S0016-5085(18)30995-8.CrossRef

41.

Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2015;13(6):1058–67.e1. https://doi.org/10.1016/j.cgh.2014.10.013.CrossRef

42.

Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31(12):4865–82. https://doi.org/10.1007/s00464-017-5431-2.CrossRefPubMed

43.

Ganz RA, Edmundowicz SA, Taiganides PA, Lipham JC, Smith CD, De Vault KR, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2016;14(5):671–7. https://doi.org/10.1016/j.cgh.2015.05.028Five year follow up of an initial multicenter trial of patients receiving MSA which showed a significant decrease in GERD-HRQL scores, moderate to severe regurgitation symptoms and PPI use (100% of patients initially to 15.3% of patients at follow up). CrossRef

44.

Skubleny D, Switzer NJ, Dang J, Gill RS, Shi X, de Gara C, et al. LINX((R)) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078–84. https://doi.org/10.1007/s00464-016-5370-3.CrossRefPubMed

45.

Tatum JM, Lipham JC. Extraluminal approaches to gastroesophageal reflux disease. Thorac Surg Clin. 2018;28(4):521–6. https://doi.org/10.1016/j.thorsurg.2018.07.003.CrossRefPubMed

46.

Hunter JG, Kahrilas PJ, Bell RC, Wilson EB, Trad KS, Dolan JP, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology. 2015;148(2):324–33.e5. https://doi.org/10.1053/j.gastro.2014.10.009.CrossRefPubMed

47.

Testoni PA, Testoni S, Mazzoleni G, Vailati C, Passaretti S. Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study. Surg Endosc. 2015;29(9):2770–80. https://doi.org/10.1007/s00464-014-4008-6.CrossRefPubMed

48.

Trad KS, Barnes WE, Prevou ER, Simoni G, Steffen JA, Shughoury AB, et al. The TEMPO Trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov. 2018;25(2):149–57. https://doi.org/10.1177/1553350618755214.CrossRefPubMedPubMedCentral

49.

Satodate H, Inoue H, Yoshida T, Usui S, Iwashita M, Fukami N, et al. Circumferential EMR of carcinoma arising in Barrett’s esophagus: case report. Gastrointest Endosc. 2003;58(2):288–92. https://doi.org/10.1067/mge.2003.361.CrossRefPubMed

50.

Inoue H, Ito H, Ikeda H, Sato C, Sato H, Phalanusitthepha C, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. Ann Gastroenterol. 2014;27(4):346–51.PubMedPubMedCentral

51.

Inoue H, Sumi K, Tatsuta T, Ikebuchi Y, Tuason J. 998 clinical results of antireflux mucosectomy (ARMS) for refractory Gerd. Gastrointest Endosc. 2017;85(5):AB120. https://doi.org/10.1016/j.gie.2017.03.196Research describing experience and results of a novel technique currently used in Japan for refractory GERD. This 67 patient cohort study, expanding on an initial pilot study, shows significant decrease in reflux symptoms, endoscopic flap valve grade, percent time clearance pH, and PPI use 1 year post procedure.CrossRef

52.

Kappelle WF, Bredenoord AJ, Conchillo JM, Ruurda JP, Bouvy ND, van Berge Henegouwen MI, et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial. Aliment Pharmacol Ther. 2015;42(5):614–25. https://doi.org/10.1111/apt.13306.CrossRefPubMed

Title: New Developments in the Diagnosis and Management of Gastroesophageal Reflux
Authors: Yan Jiang, MD
John O. Clarke, MD
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Esophagitis
Gastroesophageal Reflux Disease
Published in: Current Treatment Options in Gastroenterology / Issue 1/2020
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-020-00275-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

New Developments in the Diagnosis and Management of Gastroesophageal Reflux

Abstract

Purpose of review

Recent findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2020

Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance

Minor esophageal functional disorders: are they relevant?

The Use of Attachment Devices to Aid in Adenoma Detection

Rumination Syndrome: Recognition and Treatment

The Effects of Bariatric Surgery and Endoscopic Bariatric Therapies on GERD: An Update

Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page